Clinical trials
Pulmonary Disease, Chronic Obstructive trials in South Africa
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
91 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 7 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 8 |
| 2010 | 6 |
| 2011 | 12 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 82 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 21 |
| AstraZeneca | 19 |
| Boehringer Ingelheim | 17 |
| Novartis Pharmaceuticals | 9 |
| Pfizer | 4 |
| Sanofi | 4 |
| Bayer | 2 |
| Chiesi Farmaceutici S.p.A. | 2 |
| Hoffmann-La Roche | 2 |
| Novartis | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Disease, Chronic Obstructive | 91 |
| Bronchitis, Chronic | 4 |
| Lung Diseases | 4 |
| Asthma | 3 |
| Bronchitis | 2 |
| Inflammation | 2 |
| Lung Diseases, Obstructive | 2 |
| Tuberculosis | 2 |
| Bronchial Diseases | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
Trials
Showing 1 to 25 of 91. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.